These findings support the idea that even though GAS-mediated activation of IL-1β is likely to vary depending on infection context and bacterial strain, precise therapeutic targeting of IL-1β during the many stages of GAS infection may be an attractive strategy regardless of specific strain or infection type. The gene discussed is IL1B; the disease is infection.